Related Experiment Video

Updated: Jun 12, 2026

A High-Throughput Multiplexed Screening for Type 1 Diabetes, Celiac Diseases, and COVID-19
06:46

A High-Throughput Multiplexed Screening for Type 1 Diabetes, Celiac Diseases, and COVID-19

Published on: July 5, 2022

Identification and Follow-up of At-Risk Children Mitigate Disease Severity and Improve Treatment Outcomes in Type 1

Oona Kähkönen1,2, Salla Kuusela2,3, Jutta E Laiho4

  • 1Celiac Disease Research Center, Tampere University and Tampere University Hospital, Tampere, Finland.

Diabetes Care
|June 11, 2026
PubMed

Insights

Population screening for type 1 diabetes (T1D) identifies at-risk children who experience milder diagnoses. Early detection through programs like DIPP leads to better health outcomes and reduced T1D complications.

Area of Science:

  • Endocrinology
  • Pediatrics
  • Genetics

Background:

  • Population-based genetic screening for type 1 diabetes (T1D) is gaining interest.
  • Limited data exists on treatment outcomes for individuals identified via screening.

Purpose of the Study:

  • To compare clinical presentation and 1-year treatment outcomes in children with T1D identified through the DIPP screening program versus those diagnosed outside the program.

Main Methods:

  • A cohort of 126 at-risk children from the DIPP study was compared with 440 children diagnosed with T1D outside the screening program.
  • Characteristics at diagnosis and 1-year treatment outcomes were analyzed.

Main Results:

  • DIPP participants showed significantly lower rates of ketoacidosis, dehydration, and intensive care needs.
  • DIPP participants had lower HbA1c levels and insulin requirements at diagnosis and 1-year follow-up.
  • Inpatient stays were shorter for DIPP participants.

Conclusions:

  • Children identified through T1D screening (DIPP) present with milder clinical symptoms at diagnosis.
  • Screening leads to improved glycemic control and reduced insulin needs in the first year post-diagnosis.
Abstract

More Related Videos

Bioluminescent Monitoring of Graft Survival in an Adoptive Transfer Model of Autoimmune Diabetes in Mice10:03

Bioluminescent Monitoring of Graft Survival in an Adoptive Transfer Model of Autoimmune Diabetes in Mice

Published on: November 18, 2022

Related Concept Videos

Diabetes Mellitus: Overview and Type I Subtype01:22

Diabetes Mellitus: Overview and Type I Subtype

Diabetes mellitus is a chronic metabolic disorder characterized by high blood glucose levels due to inadequate insulin production, insulin resistance, or both. The condition affects millions worldwide and can significantly impact their health and quality of life.
Type 1 diabetes is an autoimmune disease in which the immune system mistakenly attacks and destroys the insulin-producing beta cells in the pancreas. As a result, the body is unable to produce sufficient insulin, and individuals with...
Type I Diabetes I: Introduction01:12

Type I Diabetes I: Introduction

Type 1 diabetes mellitus is a chronic metabolic disorder characterized by an absolute deficiency of insulin resulting from the autoimmune destruction of pancreatic β-cells. Although it can occur at any age, it is most commonly diagnosed in childhood, adolescence, or early adulthood. The loss of insulin production impairs cellular glucose uptake, resulting in persistent hyperglycemia and necessitating lifelong insulin therapy.Autoimmune Destruction of β-CellsThe hallmark of type 1 diabetes is an...
Diabetes Mellitus: Type 2 and Gestational01:22

Diabetes Mellitus: Type 2 and Gestational

Type 2 diabetes, characterized by insulin resistance, arises when the insulin receptors on cells lose responsiveness to insulin, diminishing the cell's capacity to take up glucose, resulting in elevated blood glucose levels. To receive a diagnosis of Type 2 diabetes, a series of blood glucose tests are necessary to assess whether the blood glucose falls within normal parameters. If the result is out of the normal range, a patient may be diagnosed as prediabetic or diabetic, depending on the...
Type I Diabetes II: Pathophysiology01:26

Type I Diabetes II: Pathophysiology

Type 1 diabetes mellitus arises from an immune-mediated destruction of pancreatic β-cells, resulting in an absolute deficiency of insulin. This process develops in genetically susceptible individuals when autoimmunity, environmental exposures, and immunologic dysregulation converge to trigger a targeted attack on the insulin-producing cells of the pancreas. The β-cells are located within the islets of Langerhans and are essential for regulating blood glucose by facilitating cellular uptake of...
Type I Diabetes III: Clinical Manifestations01:19

Type I Diabetes III: Clinical Manifestations

Type 1 diabetes mellitus typically presents with rapid-onset symptoms due to the body’s inability to utilize glucose in the absence of insulin. Since insulin is required for glucose uptake into cells, its deficiency leads to hyperglycemia and cellular energy deprivation, resulting in characteristic clinical features.Polyuria and PolydipsiaOne of the earliest, most prominent symptoms is polyuria (excessive urination). When blood glucose concentrations rise above the renal threshold, the kidneys...
Diabetes: Management and Pharmacotherapy01:15

Diabetes: Management and Pharmacotherapy

The therapy for diabetes aims to alleviate hyperglycemia-related symptoms, prevent acute metabolic decompensation, and reduce chronic end-organ complications. Glycemic control is evaluated through short-term (self-monitoring, continuous glucose monitoring) and long-term (A1c, fructosamine) metrics, enabling near real-time tracking of blood glucose levels and reflecting glycemic control over specific time frames.
Insulin remains the cornerstone of treatment for most patients with type 1 and many...